Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics, Inc. (AQST)
:AQST
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.12 - $5.80
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.29M
Market Cap
$481.48M
Enterprise Value$394.49M
Total Cash (Recent Filing)$60.54M
Total Debt (Recent Filing)$126.26M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 10, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding120,973,630
10 Day Avg. Volume1,908,509
30 Day Avg. Volume1,290,233
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit14.63
Enterprise Value/Ebitda-8.82
Forecast
1Y Price Target
$8.79Price Target Upside120.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Commercialization PathThese deals provide Aquestive with financial runway extending through 2027 and help establish a clear path to commercialization.
FDA Approval ProcessManagement indicated that their interactions with the FDA have been smooth, which is a positive sign for the approval process.
Strategic FundingA $75M strategic funding agreement with RTW Investments has been secured, contingent on FDA approval of Anaphylm.
Bears Say
Financial OverhangAn $85M underwritten equity offering of 21.25M shares has been priced at $4.00 per share, which removes a financial overhang that has weighed on the stock.
Stock VolatilityPotential volatility in the stock could arise depending on whether the FDA decides to hold an advisory committee meeting for Anaphylm.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics, Inc.’s price range in the past 12 months?
Aquestive Therapeutics, Inc. lowest stock price was $2.12 and its highest was $5.80 in the past 12 months.
What is Aquestive Therapeutics, Inc.’s market cap?
Aquestive Therapeutics, Inc.’s market cap is $481.48M.
When is Aquestive Therapeutics, Inc.’s upcoming earnings report date?
Aquestive Therapeutics, Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 76 days.
How were Aquestive Therapeutics, Inc.’s earnings last quarter?
Aquestive Therapeutics, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.167 by $0.027.
Is Aquestive Therapeutics, Inc. overvalued?
According to Wall Street analysts Aquestive Therapeutics, Inc.’s price is currently Undervalued.
Does Aquestive Therapeutics, Inc. pay dividends?
Aquestive Therapeutics, Inc. does not currently pay dividends.
What is Aquestive Therapeutics, Inc.’s EPS estimate?
Aquestive Therapeutics, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Aquestive Therapeutics, Inc. have?
Aquestive Therapeutics, Inc. has 120,973,630 shares outstanding.
What happened to Aquestive Therapeutics, Inc.’s price movement after its last earnings report?
Aquestive Therapeutics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.167. Following the earnings report the stock price went down -2.073%.
Which hedge fund is a major shareholder of Aquestive Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AQST
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.79 (120.85% Upside)
$8.79 (120.85% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.65%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
-20.33%
Trailing 12-Months
Company Description
Aquestive Therapeutics, Inc.
Aquestive Therapeutics (AQST) is a biopharmaceutical company focused on developing innovative therapies for patients with rare and complex diseases. The company specializes in the development of novel drug delivery technologies and formulations, primarily targeting therapeutic areas such as central nervous system disorders, including epilepsy and pain management. Its core products include the Suboxone Film for opioid dependence and the Libervant (diazepam) buccal film for the treatment of acute repetitive seizures.
AQST Company Deck
AQST Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the development and pre-launch activities for Anaphylm, indicating promising market expansion opportunities. However, financial challenges, including revenue decline and increased net loss, along with market access barriers, present notable concerns.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$8.79
▲(120.85% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
Esperion
―
Journey Medical Corp
―
Ownership Overview
13.63% Insiders
6.43% Mutual Funds
19.22% Other Institutional Investors
52.88% Public Companies and
Individual Investors